Blood pressure-lowering for secondary prevention of stroke: ACE inhibition is the key

Stroke

Volumn 34, Issue 5, 2003, Pages 1333-1334

  Anderson, Craig ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Angiotensin converting enzyme inhibitors; Blood pressure; Stroke prevention

Indexed keywords

ATENOLOL; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INDAPAMIDE; LOSARTAN; PERINDOPRIL; RAMIPRIL;

BLOOD PRESSURE REGULATION; CLINICAL TRIAL; DRUG EFFECT; DRUG MECHANISM; ENZYME INHIBITION; HUMAN; PRIORITY JOURNAL; SECONDARY PREVENTION; SHORT SURVEY; STROKE;

AGED; AGED, 80 AND OVER; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ARTERIOSCLEROSIS; BLOOD PRESSURE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIALS; DIURETICS; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION; INDAPAMIDE; MIDDLE AGED; PERINDOPRIL; VENTRICULAR REMODELING;

EID: 0037628820     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000069266.99057.BF     Document Type: Short Survey

References (10)

1. Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145-153.
2. Progress Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358:1033-1041.
3. Hankey GJ, Warlow CP. Treatment and secondary prevention of stroke: evidence, costs, and effects on individuals and populations. Lancet. 1999; 354:1457-1463.
4. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet. 2000;356:1955-1964.
5. MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke, and coronary heart disease, I: prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 1990;335:765-774.
6. Rodgers A, Neal B, MacMahon S. The effects of blood pressure lowering in cerebrovascular disease: an overview of randomized controlled trials. Neurol Rev Int. 1997;12:12-15.
7. Lonn EM, Yusuf S, Jha P. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation. 1994; 90:2056-2068.
8. Lonn EM, Yusuf S, Dzavik V, et al. Effects of ramipril and vitamin E on atherosclerosis: the Study to Evaluate Carotid Ultrasound changes in patients treated with Ramipril and vitamin E (SECURE). Circulation. 2001;103:919-925.
9. MacMahon S, Sharpe N, Gamble G, et al. Randomised, placebocontrolled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. J Am Coll Cardiol. 2000;36:438-443.
10. Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:1004-1010.